Recent Updates
Recently added Catalysts
IMRN Neutral Sentiment Score: 60/100

Market Announcement 5 March 2024 Immuron Limited (ASX: IMC) - Trading Halt Description The securities of Immuron Limited ( IMC') will be placed in trading halt at the request of IMC, pending it releasing an announcement.

Key Takeaway: Immuron Limited (ASX: IMC; NASDAQ: IMRN) has requested a trading halt pending the announcement of top-line results from its Phase 2 IMM-124E clinical trial. According to ASX Listing Rule 17.1, this halt will remain in effect until the announcement is made or normal trading resumes on March 7, 2024. The company has indicated that it is not aware of any issues that would prevent the halt from being granted.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immuron is preparing to release potentially important clinical trial data.
  • The trading halt allows for proper analysis of the Phase 2 clinical trial results.
  • A strategic pause in trading can create a clearer understanding of market reactions post-announcement.

Full Press Release Details

Immuron Limited (ASX: IMC)
The securities of Immuron
Limited ( IMC') will be placed in trading halt at the request of IMC, pending it releasing an announcement. Unless ASX decides
otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 7 March 2024
or when the announcement is released to the market.
5 March 2024 Market Announcement 1/1
ASX Limited ASX Customer Service Centre 131 279 | asx.com.au
Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
Level 50, South Tower, Rialto
525 Collins St Melbourne VIC 3000
Request for Trading Halt
In accordance with ASX
Listing Rule 17.1, Immuron Limited (ASX: IMC; NASDAQ: IMRN) (the Company) requests an immediate trading halt in respect of its securities.
This trading halt is requested to allow Immuron to analyse and interpret data prior to making an announcement of Phase 2 IMM-124E clinical
trial top-line results.
The Company requests that
trading in its securities be halted until after the expected announcement is made or until the market opens on 7 March 2024, whichever
The Company is not aware of
any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading
Please contact me if you
require any further information.
Immuron Limited ABN 80 063 114 045 Australia: +61 3 8892 4854
www.immuron.com USA and Canada: +1 (213) 817-5756

Frequently Asked Questions

What is the reason for Immuron's trading halt?

Immuron Limited requested a trading halt to analyze data before announcing Phase 2 IMM-124E trial results.

When will Immuron's securities resume normal trading?

Trading in Immuron's securities will resume on March 7, 2024, or after their announcement.

What does ASX Listing Rule 17.1 refer to?

ASX Listing Rule 17.1 allows companies like Immuron to request a trading halt for important announcements.

How can I contact Immuron Limited for more information?

You can contact Immuron Limited at their Australia or USA office numbers provided on their website.

Is there any new information about the trading halt?

The Company is not aware of any additional information affecting the trading halt request.

Last updated: Mar 5, 2024